IMMUCELL Insider Brigham Files Form 4 on 3/24/26

TL;DR

**Insider Michael F. Brigham filed a Form 4 for ImmuCell, signaling a change in his ownership.**

AI Summary

This Form 4 filing indicates that Michael F. Brigham, a reporting insider, filed a statement of changes in beneficial ownership of securities on March 24, 2026, for the period ending March 20, 2026. The filing is associated with ImmuCell Corp /DE/, a company in the In Vitro & In Vivo Diagnostic Substances sector. While the filing itself doesn't detail specific transactions, it signals that an insider's holdings have changed, which is important for investors as insider activity can sometimes precede significant company events or reflect management's confidence (or lack thereof) in the company's future.

Why It Matters

This filing signals a change in an insider's ownership, which can be a key indicator for investors trying to understand management's perspective on the company's value.

Risk Assessment

Risk Level: low — This filing is purely administrative, reporting a change in beneficial ownership, and does not inherently indicate high risk without transaction details.

Analyst Insight

A smart investor would note this insider filing and then seek out the full Form 4 document to understand the specific transactions (buy/sell, amount, price) to gauge the insider's sentiment towards ImmuCell Corp /DE/.

Key Players & Entities

• BRIGHAM MICHAEL F (person) — Reporting insider
• IMMUCELL CORP /DE/ (company) — Issuer of securities
• 0001136544 (person) — CIK of Michael F. Brigham
• 0000811641 (company) — CIK of ImmuCell Corp /DE/

FAQ

Filing Documents

• rdgdoc.html (4)
• rdgdoc.xml (4) — 7KB
• 0001437749-26-009661.txt ( ) — 8KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * BRIGHAM MICHAEL F (Last) (First) (Middle) C/O IMMUCELL CORPORATION 56 EVERGREEN DRIVE (Street) PORTLAND MAINE 04103 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol IMMUCELL CORP /DE/ [ ICCC ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/20/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, par value $.01 per share 03/20/2026 M 25,000 (1) A $ 5.84 229,752 D Common Stock, par value $.01 per share 03/20/2026 F 24,052 (2) D $ 6.07 205,700 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options (right to buy) $ 5.84 03/20/2026 M 25,000 02/10/2017 02/10/2027 Common Stock 25,000 $ 0 0 D Explanation of Responses: 1. Number of shares resulting from stock-for-stock exercise of stock option. The Reporting Person surrendered previously owned shares in full payment of the exercise price for that option. 2. Number of shares surrendered to the Issuer in payment of the exercise price of the option. /s/ Timothy C. Fiori Attorney-in-Fact 03/24/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)

View Full Filing

View this 4 filing on SEC EDGAR